Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index; 17 of the 34 sources its claims cite were checked for support.
Abstract
BACKGROUND: Obstructive sleep apnea is characterized by disordered breathing during sleep and is associated with major cardiovascular complications; excess adiposity is an etiologic risk factor. Tirzepatide may be a potential treatment. METHODS: We conducted two phase 3, double-blind, randomized, controlled trials involving adults with moderate-to-severe obstructive sleep apnea and obesity. Participants who were not receiving treatment with positive airway pressure (PAP) at baseline were enrolled in trial 1, and those who were receiving PAP therapy at baseline were enrolled in trial 2. The participants were assigned in a 1:1 ratio to receive either the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or placebo for 52 weeks. The primary end point was the change in the apnea-hypopnea index (AHI, the number of apneas and hypopneas during an hour of sleep) from baseline. Key multiplicity-controlled secondary end points included the percent change in AHI and body weight and changes in hypoxic burden, patient-reported sleep impairment and disturbance, high-sensitivity C-reactive protein (hsCRP) concentration, and systolic blood pressure. RESULTS: At baseline, the mean AHI was 51.5 events per hour in trial 1 and 49.5 events per hour in trial 2, and the mean body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) was 39.1 and 38.7, respectively. In trial 1, the mean change in AHI at week 52 was -25.3 events per hour (95% confidence interval [CI], -29.3 to -21.2) with tirzepatide and -5.3 events per hour (95% CI, -9.4 to -1.1) with placebo, for an estimated treatment difference of -20.0 events per hour (95% CI, -25.8 to -14.2) (P<0.001). In trial 2, the mean change in AHI at week 52 was -29.3 events per hour (95% CI, -33.2 to -25.4) with tirzepatide and -5.5 events per hour (95% CI, -9.9 to -1.2) with placebo, for an estimated treatment difference of -23.8 events per hour (95% CI, -29.6 to -17.9) (P<0.001). Significant improvements in the measurements for all prespecified key secondary end points were observed with tirzepatide as compared with placebo. The most frequently reported adverse events with tirzepatide were gastrointestinal in nature and mostly mild to moderate in severity. CONCLUSIONS: Among persons with moderate-to-severe obstructive sleep apnea and obesity, tirzepatide reduced the AHI, body weight, hypoxic burden, hsCRP concentration, and systolic blood pressure and improved sleep-related patient-reported outcomes. (Funded by Eli Lilly; SURMOUNT-OSA ClinicalTrials.gov number, NCT05412004.).
Overview
CoChat Summary
## TL;DR
In two 52-week phase 3 randomized controlled trials of adults with moderate-to-severe obstructive sleep apnea and obesity, tirzepatide improved apnea-hypopnea index (AHI) and multiple secondary outcomes versus placebo. The paper concludes that tirzepatide reduced sleep-disordered breathing, body weight, hypoxic burden, hsCRP, systolic blood pressure, and improved sleep-related patient-reported outcomes.
## Key findings
- In trial 1, the mean change in AHI at week 52 was -25.3 events/hour with tirzepatide versus -5.3 events/hour with placebo; the estimated treatment difference was -20.0 events/hour (95% CI, -25.8 to -14.2; P<0.001).
- In trial 2, the mean change in AHI at week 52 was -29.3 events/hour with tirzepatide versus -5.5 events/hour with placebo; the estimated treatment difference was -23.8 events/hour (95% CI, -29.6 to -17.9; P<0.001).
- In the pooled analysis, participants receiving tirzepatide had significant reductions in PROMIS-SRI and PROMIS-SD T scores, and both trials showed significant reductions in body weight, systolic blood pressure, and hsCRP concentrations.
- The paper states that the most frequently reported adverse events with tirzepatide were gastrointestinal and generally mild-to-moderate; adverse events occurred in 79.8% vs 76.7% of participants in trial 1 and 83.2% vs 72.8% in trial 2 (tirzepatide vs placebo).
## Methods
- Two 52-week, phase 3, multicenter, parallel-group, double-blind, randomized, controlled trials were conducted at 60 sites across nine countries.
- Adults with moderate-to-severe obstructive sleep apnea (AHI ≥15 events/hour) and obesity (BMI ≥30; ≥27 in Japan) were enrolled; trial 1 included participants unable or unwilling to use PAP, and trial 2 included participants using PAP for at least 3 consecutive months and planning to continue.
- Participants were randomized 1:1 to weekly tirzepatide (10 mg or 15 mg maximum tolerated dose) or placebo; the primary endpoint was change in AHI from baseline, with key secondary endpoints including AHI percent change, body weight, hypoxic burden, hsCRP, patient-reported sleep outcomes, and systolic blood pressure. Analyses used ANCOVA and logistic regression, with multiplicity control via a graphical testing procedure.
## Limitations
- The paper states that the shorter duration of the trials does not support assessment of long-term cardiovascular outcomes.
- The trials excluded participants without obesity and did not assess people with overweight or normal BMI.
- The trials were not designed to test whether results differed by baseline symptoms, and trial 2 was not designed to assess PAP adherence effects; also, the minimum clinically important changes for PROMIS-SRI and PROMIS-SD were not established.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
14 Valid · 0 Not valid · 6 Not checked · 57 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Excess adiposity is a major reversible etiologic risk factor for obstructive sleep apnea and its complications. 8,9”
What the sources say
- Supportedcites [8] 8. Hudgel DW, Patel SR, Ahasic AM, et al. The role of weight management in the treatment of adult obstructive sleep apnea: an official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med 2018;198(6):e70-e87. [PubMed: 30215551] source
The Introduction says weight gain is linked to the development and worsening of OSA and that obesity aggravates its metabolic and cardiovascular comorbidities. “Putting It All Together” reports that weight loss consistently improves OSA severity and may improve associated health outcomes, supporting reversibility. (LLM, conf=0.90)
- Not checked — no full text of the sourcecites [9] 9. Morgenthaler TI, Kapen S, Lee-Chiong T, et al. Practice parameters for the medical therapy of obstructive sleep apnea. Sleep 2006;29:1031-5. [PubMed: 16944671] source
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This level of weight reduction has been difficult to accomplish with lifestyle intervention alone. 35”
What the sources say
- Partly supportedcites [35] 35. Dombrowski SU, Knittle K, Avenell A, Araújo-Soares V, Sniehotta FF. Long term maintenance of weight loss with non-surgical interventions in obese adults: systematic review and meta-analyses of randomised controlled trials. BMJ 2014;348:g2646. [PubMed: 25134100] sourceExperimental — accuracy not yet measured
The Introduction says few people maintain weight loss over the long term, and the Behavioural/lifestyle v control section reports a modest mean difference of −1.56 kg at 12 months. This supports the general difficulty of sustaining weight loss with lifestyle intervention, but the claim does not specify what “this level” is, so the paper cannot verify that particular level. (LLM, conf=0.78)
- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The potential issue of PAP confounding of the PROMIS outcomes in trial 2 was minimized by a 7-day PAP washout period. 22”
What the sources say
- Partly supportedcites [22] 22. Schwarz EI, Stradling JR, Kohler M. Physiological consequences of CPAP therapy withdrawal in patients with obstructive sleep apnoea-an opportunity for an efficient experimental model. J Thorac Dis 2018;10:Suppl 1:S24-S32. [PubMed: 29445525] sourceExperimental — accuracy not yet measured
The Physiological effects of CPAP withdrawal section reports that OSA recurred and subjective sleepiness increased one week after CPAP withdrawal, supporting the rationale for a washout. It does not assess PROMIS outcomes or establish that seven days minimized PAP confounding in trial 2; sleepiness continued to increase at two weeks. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The safety profile of tirzepatide was consistent with that observed in previous trials. 14,3739”
What the sources say
- Not checked — no full text of the sourcecites [14] 14. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022;387:205-16. [PubMed: 35658024] source
- Supportedcites [37] 37. Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebocontrolled, phase 3 trial. Lancet 2023;402:613-26. [PubMed: 37385275] source
The Discussion explicitly states that tirzepatide’s safety profile was consistent with previous findings in the SURMOUNT-1 and SURPASS trials. The Safety section also describes the adverse events observed in this trial. (LLM, conf=0.95)
- Supportedcites [38] 38. Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med 2023;29:2909-18. [PubMed: 37840095] source
The Discussion explicitly states that tirzepatide’s safety profile in this trial was consistent with findings from previous tirzepatide trials. It also notes modestly higher rates of gastrointestinal adverse events and treatment discontinuation than in the tirzepatide 15 mg group in SURMOUNT-1; that qualification does not negate the overall comparison. (LLM, conf=0.95)
- Partly supportedcites [39] 39. Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA 2024;331:38-48. [PubMed: 38078870] sourceExperimental — accuracy not yet measured
The Results (Adverse Events and Tolerability; page unavailable) describe tirzepatide’s safety findings, including gastrointestinal events and serious adverse events. The passages do not compare that safety profile with previous trials, so the claimed consistency with earlier findings is not established by our copy. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were five cases of severe or serious depressive disorder or suicidal ideation or behavior events across both trials (two with tirzepatide and three with placebo).”
plainn = 5- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
29 more claims
Create a free account to see all 77 claims and every source verdict.
- Probably not a substantial claim. 29
- It may state two separate claims as one. 31
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“However, some studies were designed for other purposes17,18,30,41–44—for example, prevention of CVD or T2D.”
From A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults (2025) · cites this paper as [43]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These medications allow most patients to achieve clinically meaningful weight loss, improve severity of OSA, and improve cardiometabolic comorbidities.13,14”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These medications allow most patients to achieve clinically meaningful weight loss, improve severity of OSA, and improve cardiometabolic comorbidities.13,14”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These medications allow most patients to achieve clinically meaningful weight loss, improve severity of OSA, and improve cardiometabolic comorbidities.13,14”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SURMOUNT-OSA trial reported that tirzepatide reduced the apnea-hypopnea index by 25% to 29% over 52 weeks in individuals with obesity and moderate to severe OSA, compared with a reduction of 5.3% to 5.5% in the placebo group, regardless of the use of positive airway pressure therapy (19).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [19]
Experimental — accuracy not yet measured
16 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Benjafield, A. V., Ayas, N. T., Eastwood, P. R., Heinzer, R., Ip, M. S. M., Morrell, M. J., Nunez, C. M., Patel, S. R., Penzel, T., Pépin, J.-L., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30198-5 · Cited by 4,326
Self-citationTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Self-citationAdult Obstructive Sleep Apnea Task Force of the American Academy of Sleep Medicine, Epstein, L. J., Kristo, D., Strollo, P. J., Friedman, N., Malhotra, A., Patil, S. P., Ramar, K., Rogers, R., Schwab, R. J., et al. (2009) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.27497 · Cited by 3,360
Self-citationCPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea
McEvoy, R. D., Antic, N. A., Heeley, E., Luo, Y., Ou, Q., Zhang, X., Mediano, O., Chen, R., Drager, L. F., Liu, Z., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606599 · Cited by 2,101
Self-citationGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Adult obstructive sleep apnoea
Jordan, A. S., McSharry, D. G., & Malhotra, A. (2014) · The Lancet · doi:10.1016/s0140-6736(13)60734-5 · Cited by 1,735
Self-citationJavaheri, S., Barbe, F., Campos-Rodriguez, F., Dempsey, J. A., Khayat, R., Javaheri, S., Malhotra, A., Martinez-Garcia, M. A., Mehra, R., Pack, A. I., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.069 · Cited by 1,434
Self-citationYeghiazarians, Y., Jneid, H., Tietjens, J. R., Redline, S., Brown, D. L., El-Sherif, N., Mehra, R., Bozkurt, B., Ndumele, C. E., Somers, V. K., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000988 · Cited by 1,431
Self-citationRamar, K., Dort, L. C., Katz, S. G., Lettieri, C. J., Harrod, C. G., Thomas, S. M., & Chervin, R. D. (2015) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.4858 · Cited by 915
Azarbarzin, A., Sands, S. A., Stone, K. L., Taranto-Montemurro, L., Messineo, L., Terrill, P. I., Ancoli-Israel, S., Ensrud, K., Purcell, S., White, D. P., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehy624 · Cited by 893
Self-citation
Cited by
Items 101–200 of 823
Liu, Z., Yu, S., Jin, X., Sheng, L., Rouzi, M. R. Y., Gao, J., Lü, J., & Lei, T. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s559919 · Cited by 35
Potential Use of GLP-1 and GIP/GLP-1 Receptor Agonists for Respiratory Disorders: Where Are We at?
Janić, M., Škrgat, S., Harlander, M., Lunder, M., Janež, A., Stoian, A. P., El‐Tanani, M., Maggio, V., & Rizzo, M. (2024) · Medicina · doi:10.3390/medicina60122030 · Cited by 33
“The authors conclude that this result is clinically relevant, as a 50% reduction in AHI was proposed as clinically relevant [77].”
Mather, K. J., Mari, A., Weerakkody, G. J., Heise, T., DeVries, J. H., Urva, S., Coşkun, T., Miličević, Z., Haupt, A., & Thomas, M. K. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16159 · Cited by 24
“25,26 Changes in this or other inflammatory mediators could have contributed to treatment-related differences in the improvement in insulin sensitivity observed in this trial.”
Altobaishat, O., Gadelmawla, A. F., Balbaa, E., Turkmani, M. M., & Abouzid, M. (2025) · European Clinical Respiratory Journal · doi:10.1080/20018525.2025.2484048 · Cited by 23
“Finally, we included two studies [11,13] describing three RCTs in this systematic review and meta-analysis.”
InfluentialCVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes
Schnell, O., Almandoz, J. P., Anderson, L., Barnard-Kelly, K. D., Battelino, T., Blüher, M., Busetto, L., Catrinou, D., Ceriello, A., Cos, X., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02700-0 · Cited by 24
Anti-inflammatory effects of tirzepatide: a systematic review and meta-analysis
Masson, W., Lobo, M., Nogueira, J. P., Barbagelata, L., Touzas, P., & Frías, J. P. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-09991-4 · Cited by 21
Liu, S., Hu, J., Zhao, C., Liu, H., & He, C. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1513641 · Cited by 17
Jeyakumar, Y., Richardson, L., Sarma, S., Retnakaran, R. R., & Kramer, C. K. (2024) · BMJ Global Health · doi:10.1136/bmjgh-2024-017177 · Cited by 21
Hankosky, E. R., Desai, K. R., Chinthammit, C., Grabner, M., Stockbower, G. E., He, X., Mojdami, D., Wenziger, C. M., & Gibble, T. H. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101636 · Cited by 21
Weight Loss Blockbuster Development: A Role for Unimolecular Polypharmacology
Zhou, Q., Li, G., Hang, K., Li, J., Yang, D., & Wang, M. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-061324-011832 · Cited by 16
Bidirectional interplay of sleep apnea syndrome and cardio-vascular disorders in diabetes
Valensi, P. E., Benmohammed, K., & Zerguine, M. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111984 · Cited by 20
Pennings, N. J., Varney, C., Hines, S., Riley, B. A., Happel, P., Patel, S., & Bays, H. E. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100172 · Cited by 25
Pugliese, N. R., Paneni, F., Tricò, D., Bacca, A. V., De Biase, N., Dalpiaz, H., Mengozzi, A., Virdis, A., Ghiadoni, L., Taddei, S., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02778-6 · Cited by 16
“It may also alleviate common comorbidities associated with HF progression, such as obstructive sleep apnea [142], potentially slowing the transition to more severe HF phenotypes.”
The Expanding Scope of GLP-1 Receptor Agonists: Six Uses Beyond Diabetes
Sheth, K., Kim, S., Porterfield, L. R., Virani, S. S., Wadhwani, S., & Vaughan, E. M. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01319-6 · Cited by 21
Obesity-Related Glomerulosclerosis—How Adiposity Damages the Kidneys
Zbrzeźniak, J., Winiarska, A., Perkowska‐Ptasińska, A., & Stompór, T. P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136247 · Cited by 23
Sex Differences in Obesity and Its Treatment
Ghanta, A., Wilson, E., & Chao, A. M. (2025) · Current Psychiatry Reports · doi:10.1007/s11920-025-01601-z · Cited by 20
Incretin Receptor Agonism, Fat-free Mass, and Cardiorespiratory Fitness: A Narrative Review
Liu, Z., Weeldreyer, N. R., & Angadi, S. S. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf335 · Cited by 21
Ard, J. D., Lee, C. J., Gudzune, K. A., Addison, B., Lingvay, I., Cao, D., Mast, C. J., Stefański, A., Falcón, B. L., & Mojdami, D. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16554 · Cited by 26
Re-evaluating the concept of remission in type 2 diabetes: a call for patient-centric approaches
Khunti, K., Papamargaritis, D., Aroda, V. R., Anjana, R. M., & Kashyap, S. R. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00134-2 · Cited by 22
Fitch, A., Gigliotti, L., & Bays, H. E. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100205 · Cited by 14
“…meaningful reductions in sleep-disordered breathing have been reported in patients with moderate-to-severe obstructive sleep apnea and obesity, including a reduction in the number of apneas and hypopneas, and improvements in hypoxic burden and patient-reported sleep impairment and disturbance [30].”
Luu, S., Chan, D. E. C. Y., Marshall, N. S., Phillips, C. L., Grunstein, R. R., & Yee, B. J. (2025) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2025.102169 · Cited by 17
Self-citationMechanisms and treatment of obesity-related hypertension—Part 2: Treatments
Parvanova, A. I., Abbate, M., Reseghetti, E., & Ruggenenti, P. L. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf035 · Cited by 23
Entering a New Era in Sleep-Apnea Treatment
Patel, S. R. (2024) · New England Journal of Medicine · doi:10.1056/nejme2407117 · Cited by 17
Sleep-Disordered Breathing and Hypertension—A Systematic Review
Battisha, A., Kahlon, A., & Kalra, D. K. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14093115 · Cited by 18
Clinical Update in Heart Failure with Preserved Ejection Fraction
Krittanawong, C., Britt, W., Rizwan, A. M., Siddiqui, R., Khawaja, M., Khan, R., Joolharzadeh, P., Newman, N. A., Rivera, M. R. R., & Tang, W. H. W. (2024) · Current Heart Failure Reports · doi:10.1007/s11897-024-00679-5 · Cited by 20
Samson, S. L., Vellanki, P., Blonde, L., Hirsch, I. B., Hoang, T. D., Isaacs, S. D., Izuora, K. E., Wang, C. C. L., Ooi, C. P., Padilla, B. I., et al. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.01.006 · Cited by 35
Obstructive Sleep Apnea and Type 2 Diabetes: An Update
Gentile, S., Monda, V. M., Guarino, G., Satta, E., Chiarello, M., Caccavale, G., Mattera, E., Marfella, R., & Strollo, F. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14155574 · Cited by 24
Malhotra, A., Grunstein, R. R., Azarbarzin, A., Sands, S. A., Dang, X., Chakladar, S., Dunn, J. P., Falcón, B. L., & Bednařík, J. (2025) · Sleep Medicine · doi:10.1016/j.sleep.2025.106853 · Cited by 23
Self-citationChristensen, S. M., & Nelson, C. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100175 · Cited by 21
Strollo, P. J., Farkas, R., Taranto‐Montemurro, L., Cronin, J., Patel, S. R., SynAIRgy Investigators, Ajayi, A., Alejandrino, B., Alonso, J., Ayas, N., et al. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamag215 · Cited by 26
Hasselbalch, R. B., Andréa, M. K., Nolsøe, C. V., Hindborg, M., Yazdanfard, P. D. W., Sørensen, K. K., Blomberg, S. N. F., Christensen, H. C., Graff, C., Denholt, C. S., et al. (2025) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2025.101398 · Cited by 19
Forst, T. M., Block, C. E. M. D., Prato, S. D., Frías, J. P., Lautenbach, A., Ludvik, B. H., Marinez, M., Mathieu, C., Müller, T. D., & Schnell, O. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16247 · Cited by 15
Expanding applications of therapies based on GLP1
Drucker, D. J. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-01066-9 · Cited by 18
Fahim, S. A., Attia, Y. M., Messiha, A. A., Nabawy, A. Y., Refaat, F., & El-Maadawy, W. H. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118731 · Cited by 22
Physiology and clinical applications of GIP
Yamane, S., Harada, N., & Inagaki, N. (2025) · Endocrine Journal · doi:10.1507/endocrj.ej25-0087 · Cited by 16
Infante, M., Silvestri, F., Padilla, N., Pacifici, F., Pastore, D., Pinheiro, M. M., Caprio, M., Tesauro, M., Fabbri, A., Novelli, G., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041303 · Cited by 20
Li, Y., Sun, W., Liu, H., & Ruan, X. Z. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101761 · Cited by 22
Barana, L., De Fano, M., Cavallo, M., Manco, M., Prete, D., Fanelli, C. G., Porcellati, F., & Pippi, R. (2025) · Nutrients · doi:10.3390/nu18010131 · Cited by 13
Obesity and Atrial Fibrillation: From Mechanisms to Treatment
Dziano, J. K., Ariyaratnam, J., Middeldorp, M. E., Sanders, P., & Elliott, A. D. (2025) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.08.003 · Cited by 17
Kamrul-Hasan, A. B. M., Mondal, S., Dutta, D., Nagendra, L., Kabir, M. R., & Pappachan, J. M. (2024) · Obesity Science & Practice · doi:10.1002/osp4.70032 · Cited by 23
Park, S. K., & Choi, J. H. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14217586 · Cited by 13
Glucagon-like peptide-1 receptor agonists for the treatment of obstructive sleep apnea
D’Annibale, D. A., Mimoto, M. S., McCowen, K. C., & Malhotra, A. (2025) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001208 · Cited by 13
Self-citationThe Relationship between Upper Airway Anatomy and Obesity in Patients with Obstructive Sleep Apnea
Xu, L., Keenan, B. T., Wiemken, A. S., Staley, B. A., Benediktsdottir, B., Júlíusson, S., Pack, A. I., Gíslason, Þ., & Schwab, R. J. (2025) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202410-1027oc · Cited by 22
Self-citationSallam, M., Snygg, J., Ghandour, S. E., & Sallam, M. (2025) · Obesities · doi:10.3390/obesities5020026 · Cited by 21
Ceron, E. L., Reddy, S. D., Kattamuri, L. P. V., Muvva, D. M., Chozet, L. E., & Bright, T. M. (2025) · Journal of Brown Hospital Medicine · doi:10.56305/001c.132255 · Cited by 20
Allahwala, M. A., Marathe, C. S., Nelson, A. J., Psaltis, P. J., & Marathe, J. (2025) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.07.005 · Cited by 17
Figard, C., Messaoud, R. B., Baillieul, S., Joyeux‐Faure, M., Destors, M., Tamisier, R., Khouri, C., & Pépin, J. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103529 · Cited by 16
What will the impact be of use of tirzepatide in patients with obstructive sleep apnea (OSA)?
Pack, A. I., Grunstein, R. R., Mokhlesi, B., Ryan, S., Schwab, R., & Gozal, D. (2025) · SLEEP · doi:10.1093/sleep/zsaf045 · Cited by 14
Self-citationBreaking Ground: From CPAP Treatment to the First Medicine for OSA Patients with Obesity
Lisik, D., & Zou, D. (2025) · Current Pulmonology Reports · doi:10.1007/s13665-024-00365-w · Cited by 12
Wu, J., Lin, Y., Hsu, W., Liu, T., Tsai, Y., Huang, P., Chuang, M., Yu, T., & Lai, C. (2025) · Hepatology International · doi:10.1007/s12072-025-10857-9 · Cited by 12
Effect of GLP1 Agonists on Reproduction
Couldwell, M., Tidwell, A. J., & Taylor, A. E. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf401 · Cited by 16
The Liver in Diabetes and Metabolic Syndrome
Mahmoud, M. C., & Abdelmalek, M. F. (2025) · Clinics in Liver Disease · doi:10.1016/j.cld.2025.04.003 · Cited by 14
Kommu, S., Sharma, P., & Gabor, R. (2025) · Obesity Reviews · doi:10.1111/obr.13961 · Cited by 17
Babazadeh, D., Wyatt, S., & Steinberg, F. M. (2025) · Advances in Nutrition · doi:10.1016/j.advnut.2025.100491 · Cited by 16
Glucagon-like peptide-1 receptor agonists: a review from a cardiovascular perspective
Turkistani, Y. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1535134 · Cited by 10
Pépin, J., Baillieul, S., & Tamisier, R. (2025) · Sleep Medicine · doi:10.1016/j.sleep.2025.106491 · Cited by 13
Hunter, T. M., Chinthammit, C., Ward, J. M., Cappell, K. A., Sedgley, R., Bonafede, M., Liao, B., & Hankosky, E. R. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16330 · Cited by 13
New and future heart failure drugs
Haghighat, L., DeJong, C., & Teerlink, J. R. (2024) · Nature Cardiovascular Research · doi:10.1038/s44161-024-00576-z · Cited by 14
Insights into the Mechanism of Action of Tirzepatide: A Narrative Review
Galindo, R. J., CHENG, A. Y. Y., Longuet, C., Ai, M., Coşkun, T., Malik, R., Peleshok, J. C., Levine, J. A., & Dunn, J. P. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01804-w · Cited by 32
Self-citationTreatable Traits-Based Pharmacologic Treatment of Sleep Apnea
Lisik, D., & Zou, D. (2024) · Sleep Medicine Clinics · doi:10.1016/j.jsmc.2024.10.002 · Cited by 12
Obstructive sleep apnea, the NLRP3 inflammasome and the potential effects of incretin therapies
Wei, M., Teske, J. A., Mashaqi, S., & Combs, D. (2025) · Frontiers in Sleep · doi:10.3389/frsle.2024.1524593 · Cited by 12
The evolving landscape of obesity pharmacotherapy
Petersen, J., Finan, B., Johansen, V. B. I., Müller, T. D., & Clemmensen, C. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01427-1 · Cited by 19
Pharmacologic treatment of obesity in adults: Standards of care in overweight and obesity
C, K. A. C. M. V. R. L. J. K. A. G. A. A. A. B. B. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005729 · Cited by 36
Kamrul-Hasan, A. B. M., Patra, S., Dutta, D., Nagendra, L., Muntahi-Reza, A., Borozan, S., & Pappachan, J. M. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i2.101282 · Cited by 17
Huang, Z., Zhao, Q., Zhao, Z., THOMAS, R. J., Duan, A., Li, X., Zhang, S., Gao, L., An, C., Wang, Y., et al. (2024) · Sleep Medicine · doi:10.1016/j.sleep.2024.12.019 · Cited by 12
Sleep-Related Disorders in Patients with CKD and Kidney Transplant Recipients
Vendeville, N., Mucsi, I., & Molnar, M. Z. (2025) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000728 · Cited by 12
Sevencan, B., Steenackers, N., van Laar, A. D. E., Pazmiño, S., Buyse, B., Kalkanis, A., Testelmans, D., & der Schueren, B. V. (2025) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.11682 · Cited by 10
Ganamurali, N., & Sabarathinam, S. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01834-y · Cited by 16
Clinical Assessment of People With Obesity: Focus on Adiposity-Related Multimorbidity
Bianchettin, R. G., Gawey, B. J., Acosta, A. J., Borlaug, B. A., Caples, S. M., Collazo–Clavell, M. L., Clark, M. M., Lara-Breitinger, K. M., Lerman, A., Lerman, L. O., et al. (2025) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2025.02.021 · Cited by 16
SNAITH, J. R., Narongkiatikhun, P., Bjornstad, P., Greenfield, J. R., & Tommerdahl, K. L. (2025) · Diabetes Care · doi:10.2337/dci25-0015 · Cited by 19
Emerging role of GLP-1 agonists in cardio-metabolic therapy - Focus on Semaglutide
Odigwe, C. I., Mulyala, R. R., Malik, H., Ruiz, B., Riad, M., Sayiadeh, M. A., Honganur, S., Parks, A., Rahman, M. U., & Lakkis, N. M. (2025) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2025.100518 · Cited by 17
Glucagon-like peptide-1 medicines and cancer
Yabut, J. M., & Drucker, D. J. (2026) · Nature Cancer · doi:10.1038/s43018-025-01110-1 · Cited by 15
Alluri, A. A., Kurien, M. M., Pokar, N. P., Madarapu, A., Sadam, S., Puvvala, N., & Seetharaman, R. (2025) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2024-0193 · Cited by 13
Sleep and Sleep Disorders in Older Adults
Tobias, L. A., & Pisani, M. A. (2025) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2025.07.010 · Cited by 16
Asthma-OSA overlap syndrome: A distinct endophenotype?
Fabozzi, A., Bouloukaki, I., Bonini, M., Schiza, S. E., & Palange, P. (2025) · Respiratory Medicine · doi:10.1016/j.rmed.2025.108344 · Cited by 14
McGowan, B., Ciudin, A., Baker, J. L., Busetto, L., Dicker, D., Frühbeck, G., Goossens, G. H., Monami, M., Ragghianti, B., Sbraccia, P., et al. (2025) · Obesity Facts · doi:10.1159/000546855 · Cited by 9
Why do obesity drugs seem to treat so many other ailments?
Lenharo, M. (2024) · Nature · doi:10.1038/d41586-024-03074-1 · Cited by 17
Innovative Molecules and Delivery Technologies Enabling the Future of GLP-1-based Therapies
Xu, Y., Drucker, D. J., Traverso, G., & Beloqui, A. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf027 · Cited by 12
Tang, M., Shi, L., Guan, D., Winberg, D., Tang, T., Shao, H., & Fonseca, V. A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16466 · Cited by 8
Gholami, M., Balajam, N. Z., Rakhsha, S. S., Sajjadi‐Jazi, S. M., Shafiee, G., & Heshmat, R. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01604-w · Cited by 9
Ahmed, S., Gozal, D., & Khalyfa, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110316 · Cited by 10
Henney, A. E., Riley, D. R. J., Heague, M., Roberts, C. A., Hydes, T., Anson, M., Hughes, D. M., Alam, U., & Cuthbertson, D. J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70169 · Cited by 12
Hoffmann, K., Michalak, M., Rizzo, M., Maggio, V., & Paczkowska, A. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2586703 · Cited by 8
“Malhotra et al. demonstrated benefits in obstructive sleep apnea, and Loomba et al. reported histological improvements in meta-bolic-associated steatohepatitis (MASH) [61,62].”
Zupec, J. F., Munger, R., Scaletta, A., & Quinn, D. H. (2025) · Nutrition in Clinical Practice · doi:10.1002/ncp.11279 · Cited by 9
Wadden, T., Oquendo, M. A., Kushner, R. F., Cao, D., Karanikas, C. A., Kechter, A., & Murphy, M. A. (2026) · Obesity · doi:10.1002/oby.70122 · Cited by 16
Divo, M. J., Martínez‐García, M. Á., González, M., Campos‐Rodríguez, F., Lloberes, P., Marín‐Oto, M., Forner, M., Sánz-Rubio, D., Nieto, D., Celli, B. R., et al. (2025) · European Respiratory Journal · doi:10.1183/13993003.00519-2025 · Cited by 10
Sleep Alterations and Cognitive Decline
Lucey, B. P. (2025) · Seminars in Neurology · doi:10.1055/a-2557-8422 · Cited by 10
Alhomoud, I. S., Wheeler, S. E., & Dixon, D. L. (2025) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0038 · Cited by 14
Availability of Cardioprotective Medications for Type 2 Diabetes in the Medicaid Program
Makam, A. N., Bailey, L. R. J., Anderson, N., Bellitti, K., Skinner, S., & Nguyen, O. K. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-01449 · Cited by 10
Vilsbøll, T., Malecki, M. T., Sharma, P., Thieu, V. T., Chivukula, K. K., & Kiljanski, J. I. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16592 · Cited by 12
Using Second-Generation Anti-Obesity Medications
Schmitz, S. H., & Aronne, L. J. (2024) · Diabetes Spectrum · doi:10.2337/dsi24-0002 · Cited by 11
Henney, A. E., Riley, D. R. J., Anson, M., Azmi, S., Alam, U., & Cuthbertson, D. J. (2025) · Liver International · doi:10.1111/liv.70367 · Cited by 11
Troshina, E. A., Antsiferov, M. B., As, A., Galstyan, G. R., Маркова, Т. Н., Romantsova, T. I., Mazurina, N. V., & Koteshkova, O. M. K. (2025) · Problems of Endocrinology · doi:10.14341/probl13677 · Cited by 14
Challenges in Obstructive Sleep Apnea Management in Elderly Patients
Joskin, A., & Bruyneel, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13247718 · Cited by 15
Nutrient-Stimulating Hormone-Based Therapies for Obesity
Cristancho, C., Kim, D. W., & Apovian, C. M. (2024) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2024.10.006 · Cited by 8
The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis: A Review
Sheth, S., Merola, J. F., Weber, B. N., Prussick, R. B., Yeung, J., Liu, C., Glick, B. P., Reddy, S. M., Cook-Bolden, F. E., Wallace, E. B., et al. (2026) · JAMA Dermatology · doi:10.1001/jamadermatol.2026.0859 · Cited by 17
Emerging Pharmacological Approaches for the Treatment of Arterial Hypertension
Schinzari, F., Montenero, R., Cardillo, C., & Tesauro, M. (2025) · Biomedicines · doi:10.3390/biomedicines13040790 · Cited by 9
Advances in sleep research in 2024
Dauvilliers, Y. A. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(24)00486-1 · Cited by 8
Dobbie, L. J., Tolvanen, L., Alves, D., Baker, J. L., Bez, N. S., Birney, S., Bogl, L. H., Brown, A., Bullo, M., Clare, K., et al. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00122-1 · Cited by 8
Wu, J., Lin, Y., Hsu, W., Liu, T., Tsai, Y., Huang, P., Chuang, M., Yu, T., & Lai, C. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112294 · Cited by 12
Metadata
- Authors
- Malhotra, A., Grunstein, R. R., Fietze, I., Weaver, T. E., Redline, S., Azarbarzin, A., Sands, S. A., Schwab, R. J., Dunn, J. P., Chakladar, S., Bunck, M. C., & Bednarik, J.
- Affiliations
- Brigham and Women's Hospital (US)
- From the University of California, San Diego, La Jolla (A.M.); Woolcock Institute of Medical Research, Macquarie University, Royal Prince Alfred Hospital, and the University of Sydney — all in Sydney (R.R.G.); the Center of Sleep Medicine, Charité University Hospital Berlin, Berlin (I.F.); the College of Nursing, University of Illinois Chicago, Chicago (T.E.W.); the School of Nursing (T.E.W.) and Perelman School of Medicine (R.J.S.), University of Pennsylvania, Philadelphia; the Division of Sleep and Circadian Disorders, Brigham and Women’s Hospital, and Harvard Medical School — both in Boston (S.R., A.A., S.A.S.); and Eli Lilly, Indianapolis (J.P.D., S.C., M.C.B., J.B.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-10-03
- Volume
- 391
- Issue
- 13
- Pages
- 1193-1205
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC11598664
- OpenAlex
- W4399907994
- Cited by
- 871
- References
- 39
- Citations by year
- 2026: 410 · 2025: 379 · 2024: 80
- FWCI
- 245.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Physiology (medical) › Obstructive Sleep Apnea Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Apelin-related biomedical research
- Keywords
- tirzepatide, obstructive sleep apnea, obesity, GLP-1 receptor agonists, GIP receptor agonist, apnea-hypopnea index, weight loss, positive airway pressure, hypoxic burden, sleep disorders, C-reactive protein, systolic blood pressure, cardiovascular risk, anti-obesity drugs, obesity-related sleep apnea, body mass index
- MeSH terms
- Sleep Quality, Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Adult, Hypoxia, Blood Pressure, Body Weight, C-Reactive Protein, Double-Blind Method, Female, Gastric Inhibitory Polypeptide, Humans, Male, Middle Aged, Obesity, Severity of Illness Index, Treatment Outcome, Sleep Apnea, Obstructive, Maximum Tolerated Dose
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.